Why the study?
Does intravenous mexiletine reduce the frequency of ventricular tachyarrhythmias compared to lignocaine in patients with early ventricular tachyarrhythmias after acute myocardial infarction?
Does intravenous mexiletine reduce the frequency of ventricular tachyarrhythmias compared to lignocaine in patients with early ventricular tachyarrhythmias after acute myocardial infarction?
Intravenous mexiletine is more effective than lignocaine in reducing early ventricular tachyarrhythmias following acute myocardial infarction, without increasing toxicity.
Answers are grounded in this paper and cite their sources.
Supports preferring IV mexiletine to lignocaine for early post-MI ventricular arrhythmias; extends RCT evidence for class Ib agents in acute settings.
The antiarrhythmic effects of intravenously administered lignocaine and mexiletine were compared over a period of 48 hr in a randomized trial on 24 patients who developed ventricular tachyarrhythmias within 48 hr of the onset of acute myocardial infarction. Mexiletine was given as an initial bolus of 200 mg, followed by an infusion of 1 mg/min reduced to 0.5 mg/min after 1 hr. Lignocaine was given as a bolus of 100 mg, followed by an infusion of 3 mg/min reduced to 2 mg/min after 1 hr. Plasma levels of mexiletine, lignocaine, and monoethylglycinexylidide were monitored. The frequency of "complex" ventricular tachyarrhythmias was significantly lower in the mexiletine-treated group. This group of patients also had significantly fewer ventricular extrasystoles than those receiving lignocaine, the difference being most marked during the second 24 hr of treatment. Too few episodes of ventricular fibrillation occurred for statistical comment. The greater efficacy of mexiletine was not associated with increased drug toxicity.
No takes yet. Share an insight, caveat, or question.
Horowitz et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: